Metara

Metsera is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases. Launched in April 2024 with significant backing from ARCH Venture Partners and Population Health Partners, the company rapidly advanced a diverse portfolio of oral and injectable therapies. Its lead candidate, MET-097i, is an ultra-long-acting GLP-1 receptor agonist designed for once-monthly dosing, which demonstrated significant weight loss in early clinical trials. Metsera's pipeline also includes amylin analogs and unimolecular GGG (GLP-1, GIP, and Glucagon) receptor agonists. In September 2025, the company was acquired by Pfizer for approximately $4.9 billion to bolster Pfizer's metabolic and cardiovascular disease portfolio.